The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: A single‐center study of 555 patients
Muscle & Nerve · 2024
DOI: 10.1002/mus.28255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Alexander Zygmunt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Genotype, Adrenal Cortex Hormones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction/Aims Studies have demonstrated that certain genotypes in Duchenne muscular dystrophy (DMD) have milder or more severe phenotypes. These studies included individuals treated and not treated with corticosteroids and multiple sites with potentially varying standards of care. We aimed to assess genotype–phenotype correlations for age at loss of ambulation (LoA) in a large cohort of individuals with DMD treated with corticosteroids at one center.
Methods
In this retrospective review of medical records, encounters were included for individuals diagnosed with DMD if prescribed corticosteroids, defined as daily deflazacort or prednisone or high‐dose weekend prednisone, for 12 consecutive months. Encounters were excluded if the participants were taking disease‐modifying therapy. Data were analyzed using survival analysis for LoA and Fisher's exact tests to assess the percentage of late ambulatory (>14 years old) individuals for selected genotypes.
Results
Overall, 3948 encounters from 555 individuals were included. Survival analysis showed later age at LoA for exon 44 skip amenable ( p = .004), deletion exons 3–7 ( p < .001) and duplication exon 2 ( p = .043) cohorts and earlier age at LoA for the exon 51 skip amenable cohort ( p < .001) when compared with the rest of the cohort. Individuals with deletions of exons 3–7 had significantly more late ambulatory individuals than other cohorts (75%), while those with exon 51 skip amenable deletions had significantly fewer (11.9%) compared with other cohorts.
Discussion
This confirms previous observations of genotype–phenotype correlations in DMD and enhances information for trial design and clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Division of Neurology, Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
- Department of Psychology, University of Alabama, Tuscaloosa, Alabama, USA.
ORCID-Profile: Alexander Zygmunt
Zitieren
APA
Zygmunt, A., Wong, B., Moon, D., Horn, P., Rathbun, R., Lambert, J., Bange, J., Rybalsky, I., Reebals, L., & Tian, C. (2024). The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: A single‐center study of 555 patients. Muscle & Nerve. https://doi.org/10.1002/mus.28255
Vancouver
Zygmunt A, Wong B, Moon D, Horn P, Rathbun R, Lambert J, et al. The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: A single‐center study of 555 patients. Muscle & Nerve. 2024. doi:10.1002/mus.28255
BibTeX
@article{Zygmunt2024,
author = {Zygmunt, Alexander and Wong, Brenda and Moon, David and Horn, Paul and Rathbun, Richard and Lambert, Joshua and Bange, Jean and Rybalsky, Irina and Reebals, Lisa and Tian, Cuixia},
title = {The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: A single‐center study of 555 patients},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28255}
}
EUVIMED